Orthofix International N.V. (OFIX) Receives $52.75 Consensus Price Target from Analysts
Orthofix International N.V. (NASDAQ:OFIX) has been given a consensus rating of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $52.75.
A number of research firms have issued reports on OFIX. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 target price (up from $50.00) on shares of Orthofix International N.V. in a research note on Thursday, August 10th. BidaskClub cut Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. TheStreet upgraded Orthofix International N.V. from a “c+” rating to a “b-” rating in a research note on Tuesday, August 8th. Zacks Investment Research raised Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Thursday, August 10th. Finally, Ladenburg Thalmann Financial Services started coverage on Orthofix International N.V. in a report on Wednesday, June 14th. They set a “buy” rating and a $53.25 price target on the stock.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/28/orthofix-international-n-v-ofix-receives-52-75-consensus-price-target-from-analysts.html.
Shares of Orthofix International N.V. (NASDAQ:OFIX) traded up 1.55% during trading on Friday, reaching $48.36. 161,141 shares of the company’s stock traded hands. Orthofix International N.V. has a 1-year low of $32.51 and a 1-year high of $50.40. The company has a market capitalization of $878.70 million, a price-to-earnings ratio of 113.26 and a beta of 0.22. The company has a 50 day moving average of $47.80 and a 200-day moving average of $43.18.
Orthofix International N.V. (NASDAQ:OFIX) last posted its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. The company had revenue of $108.90 million for the quarter, compared to analysts’ expectations of $102.94 million. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $0.41 earnings per share. Equities analysts predict that Orthofix International N.V. will post $1.56 earnings per share for the current year.
In related news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.46, for a total transaction of $363,679.38. Following the transaction, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at $2,212,988.78. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Bradley V. Niemann sold 6,956 shares of Orthofix International N.V. stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $49.44, for a total value of $343,904.64. Following the transaction, the insider now directly owns 40,178 shares in the company, valued at $1,986,400.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,406 shares of company stock worth $1,138,531. 5.60% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Orthofix International N.V. by 18.6% during the first quarter. Vanguard Group Inc. now owns 1,815,948 shares of the medical device company’s stock worth $69,278,000 after acquiring an additional 284,482 shares during the period. Dimensional Fund Advisors LP grew its holdings in Orthofix International N.V. by 11.6% during the second quarter. Dimensional Fund Advisors LP now owns 870,120 shares of the medical device company’s stock worth $40,443,000 after acquiring an additional 90,349 shares during the period. Wellington Management Group LLP acquired a new position in Orthofix International N.V. during the first quarter worth about $20,021,000. Oakview Capital Management L.P. grew its holdings in Orthofix International N.V. by 2.9% during the first quarter. Oakview Capital Management L.P. now owns 510,699 shares of the medical device company’s stock worth $19,483,000 after acquiring an additional 14,491 shares during the period. Finally, State Street Corp grew its holdings in Orthofix International N.V. by 4.1% during the second quarter. State Street Corp now owns 481,220 shares of the medical device company’s stock worth $22,370,000 after acquiring an additional 18,741 shares during the period. 94.40% of the stock is currently owned by hedge funds and other institutional investors.
About Orthofix International N.V.
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.